CARM
Carisma Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
−22.22%Year over year
Reported trailing growth
- Revenue
- +159.7%
- EBITDA
- +122.0%
- EBIT
- +116.2%
- EPS
- +112.8%
- Free cash flow
- +67.2%
- Operating cash flow
- +66.9%
Forward estimates
Based on analyst estimates
- Revenue
- +182.0%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -9.6%
- EBITDA
- +33.8%
- EBIT
- +29.9%
- Net income
- +30.4%
- EPS
- +43.6%
- Free cash flow
- +27.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2025